Artificial lung dev Breethe raises $3m
Artificial lung developer Breethe raised approximately $3 million in an equity financing round, according to an SEC filing posted late last month. Funds raised during the round will cover the sales and issuance of Series Seed-4 preferred stock and the underlying common stock convertible from it, according to the filing. The Baltimore-based company is developing the Oxy-1 ambulatory artificial lung system which is designed for home use for patients who suffer from acute and chronic lung failure, according to its website. The system includes a portable pack, which contains the unit’s batteries, oxygen source and pump motor and controller, a pump-lung unit which it anticipates will need to be replaced every 30 days and a blood cannula connection to the heart. Breethe was formed in 2014 as a spin-out from the University of Maryland, Baltimore, utilizing licensed technology from the University. A total of 22 anonymous investors joined the $3 million round, according to the filing, with the first sale date recorded on December 13. The company is not looking to raise any more funds in the round and hasn’t officially announced the round outside the SEC filing. The post Artificial lung dev Breethe raises $3m appeared first on MassDevice.
Conclusions: In patients with FIP, PVR is a significant contributor of 6MWD, independently from the extent of fibrosis on HRCT. These results strengthen both the rationale to use 6MWD as endpoint in FIP and to target APH with specific therapies.Respiration
Jack Palmer, of Kansas City, Missouri, became the 20th infant under a year old to undergo a heart-lung transplant after he was born in January with a congenital heart defect.
We report that the disruption of excitation-contraction coupling contributes to impaired force generation in the mouse model of Sod1 deficiency. Briefly, we found a significant reduction in sarcoplasmic reticulum Ca2+ ATPase (SERCA) activity as well as reduced expression of proteins involved in calcium release and force generation. Another potential factor involved in EC uncoupling in Sod1-/- mice is oxidative damage to proteins involved in the contractile response. In summary, this study provides strong support for the coupling between increased oxidative stress and disruption of cellular excitation contraction mac...
With the development of medical technology, transplantation has prevailed and become an important tool in the treatment of disease. According to the WHO ’s statistics, as of 2015, approximately 120000 cases of solid organ transplantation have been performed globally. Renal transplantation is the most common, followed by liver transplantation, heart transplantation, lung transplantation, hematopoietic stem cell transplantation, etc. . And, in re cipients of transplantation, seizures usually occur during the postoperative period [2,3].
This thirty-fifth adult lung and heart –lung transplant report summarizes data from 64,803 adult lung and 4,054 adult heart-lung transplants performed through June 30, 2017 and reported to the International Thoracic Organ Transplant Registry. With each year's report we now also provide more detailed analyses on a particular focus theme . Since 2013, these have been donor and recipient age; retransplantation; early graft failure; indication for transplant; and allograft ischemic time; and in 2018, multiorgan transplantation.
Models of power delivery within an intact organism have been limited to ionizing radiation and to some extent sound&magnetic waves for diagnostic purposes. Traditional electrical power delivery within intact human body relies on implanted batteries that limit the amount and duration of delivered power. The efficiency of current battery technology limits substantial demand to be met; such as continuous operation of an implantable artificial heart pump within a human body.
This study aimed to evaluate the impact of agonal time and warm ischemic time on early survival in Category III donation after circulatory death (DCD) donor lung transplants (LTx) using data reported to the International Society for Heart and Lung Transplantation (ISHLT) DCD LTx Registry.
The majority of children supported with ventricular assist devices (VAD) are bridged to heart transplantation. Although bridge to recovery has been reported, low recovery patient numbers has precluded systematic analysis. The aim of this study was to delineate recovery rates, predictors of recovery, and to report the long-term follow-up after VAD explantation in children.
The past year has been notable for multiple celebrations and symposia around the globe commemorating the first heart transplant performed worldwide by Dr. Christiaan Barnard at Groote Schuur Hospital in Cape Town, South Africa, on December 3, 1967, and the first heart transplant performed in the United States by Dr. Norman Shumway at Stanford Hospital on January 6, 1968. Since then, the field of heart transplantation has grown dramatically, with steady increases in the number of heart transplants performed worldwide annually, accompanied by improvement in post-transplant survival and other favorable outcomes.
In a recently published article, Asleh et al. demonstrated that cardiac allograft recipients with a baseline serum urate higher than 7 mg/dL are at a two-fold higher risk for developing cardiac allograft vasculopathy (CAV) and that the increase in serum urate during follow-up is associated with plaque progression independently of renal function, sirolimus therapy, and other comorbidities. Εven though there are data about the role of urate in endothelial dysfunction and inflammation, the authors conclude that although serum urate may be a reliable biomarker for CAV progression, its implication in the pathogenesis of...